Cabergoline for Breast Symptoms After Pregnancy Loss
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This study tests whether a medication called cabergoline can help stop milk production and reduce breast discomfort after a pregnancy loss or abortion.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are between 12 and 18 weeks pregnant
- You are having a pregnancy loss or abortion at Maimonides Medical Center
- You have not had a mastectomy
- You are not currently breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called carbergoline to see if it can safely lower high prolactin levels caused by antipsychotic drugs. It may help reduce symptoms like breast discomfort or missed periods, and improve well-being.
This trial tests a higher dose of the drug cabergoline to see if it works better for small prolactin-secreting tumors (microprolactinomas) in premenopausal women who have not been treated before. It aims to find a safe and effective way to lower high prolactin levels and shrink the tumor.
This study looks at metabolic health (like blood sugar and cholesterol) in people with prolactinomas who are being treated with the drug cabergoline. It aims to understand how lowering prolactin affects the body's metabolism and may help guide better care for patients with this condition.
This trial compares two medications, cabergoline and bromocriptine, to see which works better for women with high prolactin levels (hyperprolactinemia). It aims to find a more effective treatment to help manage this condition, which can affect fertility and menstrual cycles.
This trial tests if cabergoline, a medicine, can help shrink nonfunctioning pituitary adenomas (benign tumors on the pituitary gland that don't produce excess hormones). It may be an option for people who have not had prior radiation or surgery, and whose tumors are at least 0.5 cm in size.
This study tests whether a medicine called cabergoline can lower the chance of ovarian hyperstimulation syndrome (OHSS) in women undergoing IVF who are at high risk. It compares cabergoline with a standard technique called 'coasting' (stopping fertility drugs for a few days).
Hear when a new Pregnancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.